Neurokinin-receptor antagonists (Formulary)

APREPITANT

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Capsules 80mg, 125mg (s)

Dosage:

As per SMC 1252/17: As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).
As per SMC 1241/17: As part of combination therapy, for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in infants, toddlers and children from the age of six months to less than 12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).

Important: Formulation and dosage details

Formulation:

Powder for oral suspension 125mg (s)

Dosage:

As per SMC 1252/17: As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).

As per SMC 1241/17: As part of combination therapy, for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in infants, toddlers and children from the age of six months to less than 12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).

 

FOSAPREPITANT

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Injection 150mg (s)

Editorial Information

Document Id: F086